查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2143808

小分子化學藥物CDMO市場：全球市場預測，2026-2032年

Small Molecule Chemical Drug CDMO Market - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 196 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，小分子化學藥物的 CDMO 市場將成長至 1,100.4 億美元，複合年成長率為 7.52%。

主要市場統計數據
基準年 2025 662.2億美元
預計年份：2026年 698.1億美元
預測年份 2032 1100.4億美元
複合年成長率 (%) 7.52%

小分子化學藥物CDMO市場概覽

小分子化學藥物的合約研發生產機構 (CDMO) 為製藥和生物技術公司提供製程開發、分析服務、規模化生產、臨床供應、商業化生產以及相關的法規遵循活動。該市場的發展受到對專業化學技術、可靠生產能力、成熟的品管體係以及貫穿整個研發階段的靈活外包服務的需求所驅動。客戶越來越重視並評估技術深度、供應鏈韌性、法規遵循記錄、安全防護能力以及在不同設施間高效轉移製程的能力。

外包、複雜性和韌性正在改變CDMO的選擇方式。

市場環境正從簡單的契約製造轉向整合、風險管理型的夥伴關係。贊助公司正將更多專業化的化學和製造活動外包，以降低其內部基礎設施的需求，利用稀缺的技術能力，並支持產量波動較大的研發項目。同時，複雜分子、高活性化合物、受管制物質、持續改進的期望以及日益嚴格的環境要求，都增加了對先進製程控制和專用設施的需求。因此，在資質認證決策中，合格、技術適用性、合規記錄、產能可見度、資料完整性、業務永續營運和技術轉移記錄等因素正日益成為綜合考量的對象。

人工智慧可以增強在開發、品質和供應方面的決策能力。

人工智慧可以透過加速合成路線和製程的分析、識別實驗模式、輔助雜質檢測以及改進程式參數的監控，對小分子化學品的合約研發生產（CDMO）運作產生影響。在生產製造方面，機器學習工具可以幫助檢測偏差、最佳化生產計劃、預測設備維護需求並加強放行資料的審核。然而，人工智慧的應用仍然依賴檢驗的數據、可解釋性、網路安全、模型管治以及明確的人工責任。短期來看，其最具實際價值的體現可能是將決策支援整合到現有的品質和生產工作流程中，而不是取代專家監督。

區域趨勢反映了製造業實力和監管重點的差異。

在北美，強勁的醫藥創新與對國內或近岸供應鏈、專業化學技術以及符合監管要求的生產的需求相結合。在歐洲，重點在於品質系統、環境績效、流程精細化以及跨境監管協調。亞太地區在化學人才、研發能力和生產規模方面仍然舉足輕重，但贊助商持續關注合規一致性和供應鏈集中度。拉丁美洲在取得區域供應和醫藥生產方面提供了機遇，但各國的基礎設施和監管協調程度不一。中東的生命科學和工業領域能力正在發展，而非洲的機會則與加強當地醫藥生產、技術技能、品質基礎設施和可靠的物流系統息息相關。

經濟和戰略集團塑造了人們對合作和合規的預期。

東協支持區域製造業和供應鏈多元化，並承認其成員國監管要求和技術能力的差異。金磚國家成員國擁有豐富的化學人才、工業基礎設施和醫藥需求，但營商環境和合規要求並不統一。歐盟受益於統一的法律規範和複雜的多邊商業運作。七國集團市場普遍高度重視完善的品管系統、供應鏈管理、資料完整性和高附加價值技術服務。海灣合作理事會成員國正在投資醫療保健和產業在地化，並對技術轉移和區域生產表現出日益濃厚的興趣。北約成員國共同強調建構具有韌性、安全可靠的醫藥供應鏈的重要性，尤其對於關鍵藥物而言。

各國的具體優先事項包括創新能力和製造業在地化等。

澳洲將研發能力與對國際互聯供應鏈的依賴結合。巴西和墨西哥是拉丁美洲重要的藥品生產和分銷中心，為當地供應鏈和監管框架提供了機會。加拿大和美國優先考慮創新、專業製造以及關鍵供應鏈的韌性。中國和印度擁有廣泛的化學和生產生態系統，但投資者仍在評估監管執法、智慧財產權保護和營運透明度。日本和韓國擁有先進的科技、對品質的重視以及精湛的工業能力。法國、德國、義大利、西班牙和英國在歐洲的製藥、化學、工程和監管領域擁有強大的專業知識。俄羅斯在化學和製藥領域擁有成熟的能力，但市場進入、制裁、物流和國際合作條件企業發展重大影響。

CDMO買家和產業領導者的行動重點

領導者在對供應商進行分類時，不應僅依據名義產能或價格，而應考慮化學複雜性、密閉要求、研發階段、劑型整合以及地理風險。合格專案應檢驗品質效能、資料完整性、變更管理規範、分析可比性、技術轉移管治以及關鍵投入和設備的復原計畫。贊助商可以透過在合理情況下採用雙重採購、早期製程開發合作、明確界定研發職責以及與可衡量的技術和品質里程碑掛鉤的階段性合約來降低執行風險。合約研發生產機構（CDMO）應優先考慮可互通的數據系統、檢驗的人工智慧應用案例、人才培養、能源和廢棄物效率以及關於產能和偏差的透明資訊共用。

調查方法執行摘要

本執行摘要採用定性且基於證據的框架，對小分子化學製藥的合約研發生產（CDMO）產業進行分析。該報告對既定的行業促進因素、製藥外包實踐、監管和品質考慮、生產技術進步、區域商業環境以及人工智慧的影響進行了綜合分析。地理分析涵蓋指定區域、經濟和安全集團以及各國。論證僅限於結構特徵和可觀察的策略主題，不包括市場估算和預測、市場佔有率、預測以及公司特定聲明。

結論：能力、合規性和韌性決定了企業的競爭地位。

小分子化學藥物的合約研發生產機構（CDMO）正從單純的生產供應商轉型為藥物研發和供應鏈管理的策略夥伴。成功的關鍵在於將化學專業知識、擴充性且合規的營運、穩健的技術轉移、靈活的採購以及數位化工具的合理運用融會貫通。那些將供應商管治與嚴格的監管合規、區域風險管理、永續性和可操作的人工智慧相結合的行業領導者，將更有能力支持複雜的研發項目和可靠的商業供應鏈。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章：小分子化學藥物CDMO市場：依服務類型分類

  • 分析測試
    • 生物分析測試
    • 雜質測試
    • 測試方法的開發
    • 穩定性測試
  • 臨床開發
    • 第一階段
    • 第二階段
    • 第三階段
    • 第四階段
  • 商業生產
    • 藥物製劑
    • 原料藥
  • 配方開發
    • 注射用藥物製劑
    • 口服製劑
    • 外用製劑
  • 臨床前開發
    • ADME
    • 藥物動力學
    • 安全評估
    • 毒性測試
  • 製程開發
    • 流程最佳化
    • 擴大規模

第8章：小分子化學藥物CDMO市場：訂單模式

  • 專用生產能力
  • 服務費
  • 風險分擔
  • 契約製造

第9章：小分子化學藥物CDMO市場：依生產規模分類

  • 臨床量表
  • 商業規模
  • 中試規模

第10章：小分子化學藥物CDMO市場：依分子類型分類

  • 藥物製劑
  • 原料藥

第11章：小分子化學藥物CDMO市場：依治療領域分類

  • 心血管系統
  • 感染疾病
  • 神經病學
  • 腫瘤學

第12章：小分子化學藥物CDMO市場：依最終用戶分類

  • 學名藥生產商
  • 大型製藥企業
  • 小規模生技公司

第13章：小分子化學藥物CDMO市場：依地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第14章：小分子化學藥物CDMO市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章：小分子化學藥物CDMO市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章 競爭格局

  • 2025年市佔率分析
  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第17章：公司簡介

  • Akums Drugs and Pharmaceuticals Ltd
  • Alcami Corporation
  • Almac Group Ltd
  • Asymchem Laboratories（Tianjin）Co Ltd
  • Aurigene Pharmaceutical Services Ltd
  • Baxter International Inc
  • Bellen Chemistry Co Ltd
  • Cambrex Corporation
  • Catalent, Inc.
  • ChemCon GmbH
  • CordenPharma International
  • Curia Inc
  • Eurofins Scientific SE
  • Evonik Industries AG
  • Jiuzhou Pharma Co Ltd
  • Lonza Group AG
  • Olon SpA
  • PCI Pharma Services Inc
  • Pharmaron Beijing Co Ltd
  • Piramal Pharma Limited
  • Porton Pharma Solutions Co Ltd
  • Recipharm AB
  • Sai Life Sciences Ltd
  • Siegfried Holding AG
  • SK Pharmteco LLC
  • Thermo Fisher Scientific Inc.
  • Viswa Laboratories Pvt Ltd
  • WuXi AppTec Co., Ltd.

第18章 主要專家

Product Code: MRR-9C4233EE7D97

The Small Molecule Chemical Drug CDMO Market is projected to grow by USD 110.04 billion at a CAGR of 7.52% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 66.22 billion
Estimated Year [2026] USD 69.81 billion
Forecast Year [2032] USD 110.04 billion
CAGR (%) 7.52%

Small-Molecule Chemical Drug CDMO Market: Executive Overview

Small-molecule chemical drug contract development and manufacturing organizations (CDMOs) support pharmaceutical and biotechnology companies with process development, analytical work, scale-up, clinical supply, commercial manufacturing, and related regulatory activities. The market is shaped by demand for specialized chemistry, reliable production capacity, quality-system maturity, and flexible outsourcing across development stages. Buyers increasingly evaluate technical depth, supply-chain resilience, regulatory performance, containment capabilities, and the ability to transfer processes efficiently between facilities.

Outsourcing, Complexity, and Resilience Are Reshaping CDMO Selection

The landscape is shifting from transactional manufacturing toward integrated, risk-managed partnerships. Sponsors are outsourcing more specialized chemistry and manufacturing activities to reduce internal infrastructure requirements, access scarce technical capabilities, and support development programs with variable volumes. At the same time, complex molecules, potent compounds, controlled substances, continuous-improvement expectations, and tighter environmental requirements are increasing the need for advanced process control and specialized facilities. Qualification decisions therefore increasingly combine cost, technical fit, compliance history, capacity visibility, data integrity, business continuity, and technology-transfer performance.

Artificial Intelligence Strengthens Development, Quality, and Supply Decisions

Artificial intelligence can influence small-molecule chemical CDMO operations by accelerating route and process analysis, identifying experimental patterns, supporting impurity investigations, and improving process-parameter monitoring. In manufacturing, machine-learning tools may help detect deviations, optimize scheduling, anticipate equipment maintenance needs, and strengthen release-data review. Adoption remains dependent on validated data, explainability, cybersecurity, model governance, and clear human accountability. The most practical near-term value is likely to come from decision support embedded in established quality and manufacturing workflows rather than from replacing expert oversight.

Regional Dynamics Reflect Different Manufacturing Strengths and Regulatory Priorities

North America combines strong pharmaceutical innovation with demand for domestic or nearshore supply assurance, specialized chemistry, and regulatory-ready production. Europe emphasizes quality systems, environmental performance, process sophistication, and cross-border regulatory coordination. Asia-Pacific remains important for chemistry talent, development capacity, and manufacturing scale, while sponsors continue to scrutinize compliance consistency and supply-chain concentration. Latin America offers opportunities linked to regional supply access and pharmaceutical production, with infrastructure and regulatory harmonization varying by country. The Middle East is developing life-science and industrial capabilities, while Africa's opportunity is tied to strengthening local pharmaceutical manufacturing, technical skills, quality infrastructure, and dependable logistics.

Economic and Strategic Blocs Shape Collaboration and Compliance Expectations

ASEAN supports regional manufacturing and supply-chain diversification, although regulatory requirements and technical capabilities differ across member states. BRICS members provide broad access to chemistry talent, industrial infrastructure, and pharmaceutical demand, but operating conditions and compliance expectations are not uniform. The European Union benefits from harmonized regulatory structures alongside complex multi-country operations. G7 markets generally place strong emphasis on advanced quality systems, supply assurance, data integrity, and high-value technical services. GCC countries are investing in healthcare and industrial localization, creating interest in technology transfer and regional production. NATO countries collectively underscore the importance of resilient, secure, and trusted pharmaceutical supply chains, especially for critical medicines.

Country-Level Priorities Range from Innovation Capacity to Manufacturing Localization

Australia combines research capability with reliance on internationally connected supply chains. Brazil and Mexico are important Latin American pharmaceutical manufacturing and distribution bases, with opportunities linked to local supply and regulatory development. Canada and the United States emphasize innovation, specialized manufacturing, and resilience in critical supply chains. China and India offer extensive chemistry and production ecosystems, while sponsors continue to assess regulatory execution, intellectual-property protection, and operational transparency. Japan and South Korea bring advanced science, quality orientation, and sophisticated industrial capabilities. France, Germany, Italy, Spain, and the United Kingdom contribute strong pharmaceutical, chemical, engineering, and regulatory expertise within Europe. Russia has established chemical and pharmaceutical capabilities, although market access, sanctions, logistics, and international collaboration conditions materially affect engagement.

Action Priorities for CDMO Buyers and Industry Leaders

Leaders should segment suppliers by chemistry complexity, containment needs, development phase, dosage-form interface, and geographic risk rather than selecting solely on nominal capacity or price. Qualification programs should test quality performance, data integrity, change-control discipline, analytical comparability, technology-transfer governance, and recovery plans for critical inputs and equipment. Sponsors can reduce execution risk through dual sourcing where justified, early process-development collaboration, clearly defined development responsibilities, and stage-gated agreements tied to measurable technical and quality milestones. CDMOs should prioritize interoperable data systems, validated AI use cases, workforce development, energy and waste efficiency, and transparent communication of capacity and deviations.

Research Methodology for the Executive Summary

This executive summary applies a qualitative, evidence-led framework to the small-molecule chemical drug CDMO domain. It synthesizes established industry drivers, pharmaceutical outsourcing practices, regulatory and quality considerations, manufacturing-technology developments, regional operating conditions, and implications of artificial intelligence. Geographic interpretation covers the specified regions, economic and security groupings, and countries. Claims are limited to structural characteristics and observable strategic themes; market estimates, market shares, forecasts, and company-specific claims are excluded.

Conclusion: Capability, Compliance, and Resilience Define Competitive Readiness

Small-molecule chemical drug CDMOs are becoming strategic contributors to pharmaceutical development and supply continuity rather than solely production vendors. Success depends on combining chemistry expertise, scalable and compliant operations, robust technology transfer, resilient sourcing, and disciplined use of digital tools. Industry leaders that align supplier governance with regulatory rigor, regional risk management, sustainability, and practical AI deployment will be better positioned to support complex development programs and dependable commercial supply.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. New Revenue Opportunities
  • 3.4. Next-Generation Business Models
  • 3.5. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Small Molecule Chemical Drug CDMO Market, by Service Type

  • 7.1. Introduction
  • 7.2. Analytical Testing
    • 7.2.1. Bioanalytical Testing
    • 7.2.2. Impurity Testing
    • 7.2.3. Method Development
    • 7.2.4. Stability Testing
  • 7.3. Clinical Development
    • 7.3.1. Phase I
    • 7.3.2. Phase II
    • 7.3.3. Phase III
    • 7.3.4. Phase IV
  • 7.4. Commercial Manufacturing
    • 7.4.1. Drug Product
    • 7.4.2. Drug Substance
  • 7.5. Formulation Development
    • 7.5.1. Injectable Formulation
    • 7.5.2. Oral Formulation
    • 7.5.3. Topical Formulation
  • 7.6. Preclinical Development
    • 7.6.1. ADME
    • 7.6.2. Pharmacokinetics
    • 7.6.3. Safety Assessment
    • 7.6.4. Toxicology Studies
  • 7.7. Process Development
    • 7.7.1. Process Optimization
    • 7.7.2. Scale Up

8. Small Molecule Chemical Drug CDMO Market, by Contract Model

  • 8.1. Introduction
  • 8.2. Dedicated Capacity
  • 8.3. Fee For Service
  • 8.4. Risk Sharing
  • 8.5. Toll Manufacturing

9. Small Molecule Chemical Drug CDMO Market, by Manufacturing Scale

  • 9.1. Introduction
  • 9.2. Clinical Scale
  • 9.3. Commercial Scale
  • 9.4. Pilot Scale

10. Small Molecule Chemical Drug CDMO Market, by Molecule Type

  • 10.1. Introduction
  • 10.2. Drug Product
  • 10.3. Drug Substance

11. Small Molecule Chemical Drug CDMO Market, by Therapeutic Area

  • 11.1. Introduction
  • 11.2. Cardiovascular
  • 11.3. Infectious Diseases
  • 11.4. Neurology
  • 11.5. Oncology

12. Small Molecule Chemical Drug CDMO Market, by End User

  • 12.1. Introduction
  • 12.2. Generics Companies
  • 12.3. Large Pharma
  • 12.4. Small Biotech

13. Small Molecule Chemical Drug CDMO Market, by Region

  • 13.1. Introduction
  • 13.2. Asia-Pacific
  • 13.3. North America
  • 13.4. Latin America
  • 13.5. Europe
  • 13.6. Middle East
  • 13.7. Africa

14. Small Molecule Chemical Drug CDMO Market, by Group

  • 14.1. Introduction
  • 14.2. ASEAN
  • 14.3. GCC
  • 14.4. European Union
  • 14.5. BRICS
  • 14.6. G7
  • 14.7. NATO

15. Small Molecule Chemical Drug CDMO Market, by Country

  • 15.1. Introduction
  • 15.2. United States
  • 15.3. Canada
  • 15.4. Mexico
  • 15.5. Brazil
  • 15.6. United Kingdom
  • 15.7. Germany
  • 15.8. France
  • 15.9. Russia
  • 15.10. Italy
  • 15.11. Spain
  • 15.12. China
  • 15.13. India
  • 15.14. Japan
  • 15.15. Australia
  • 15.16. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2025
  • 16.2. Market Concentration Analysis, 2025
    • 16.2.1. Concentration Ratio (CR)
    • 16.2.2. Herfindahl Hirschman Index (HHI)
  • 16.3. Recent Developments & Impact Analysis, 2025
  • 16.4. Product Portfolio Analysis, 2025
  • 16.5. Benchmarking Analysis, 2025

17. Company Profiles

  • 17.1. Akums Drugs and Pharmaceuticals Ltd
  • 17.2. Alcami Corporation
  • 17.3. Almac Group Ltd
  • 17.4. Asymchem Laboratories (Tianjin) Co Ltd
  • 17.5. Aurigene Pharmaceutical Services Ltd
  • 17.6. Baxter International Inc
  • 17.7. Bellen Chemistry Co Ltd
  • 17.8. Cambrex Corporation
  • 17.9. Catalent, Inc.
  • 17.10. ChemCon GmbH
  • 17.11. CordenPharma International
  • 17.12. Curia Inc
  • 17.13. Eurofins Scientific SE
  • 17.14. Evonik Industries AG
  • 17.15. Jiuzhou Pharma Co Ltd
  • 17.16. Lonza Group AG
  • 17.17. Olon S.p.A
  • 17.18. PCI Pharma Services Inc
  • 17.19. Pharmaron Beijing Co Ltd
  • 17.20. Piramal Pharma Limited
  • 17.21. Porton Pharma Solutions Co Ltd
  • 17.22. Recipharm AB
  • 17.23. Sai Life Sciences Ltd
  • 17.24. Siegfried Holding AG
  • 17.25. SK Pharmteco LLC
  • 17.26. Thermo Fisher Scientific Inc.
  • 17.27. Viswa Laboratories Pvt Ltd
  • 17.28. WuXi AppTec Co., Ltd.

18. Key Experts

LIST OF FIGURES

  • FIGURE 1. Global Small Molecule Chemical Drug CDMO Market, Years Considered for the Study
  • FIGURE 2. Global Small Molecule Chemical Drug CDMO Market, Research Design
  • FIGURE 3. Global Small Molecule Chemical Drug CDMO Market, Research Framework
  • FIGURE 4. Global Small Molecule Chemical Drug CDMO Market, Data Triangulation
  • FIGURE 5. Global Small Molecule Chemical Drug CDMO Market Size, 2017-2032 (USD Million)
  • FIGURE 6. Global Small Molecule Chemical Drug CDMO Market Size, by Service Type, 2025 vs 2032 (%)
  • FIGURE 7. Global Small Molecule Chemical Drug CDMO Market Size, by Service Type, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 8. Global Small Molecule Chemical Drug CDMO Market Size, by Contract Model, 2025 vs 2032 (%)
  • FIGURE 9. Global Small Molecule Chemical Drug CDMO Market Size, by Contract Model, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 10. Global Small Molecule Chemical Drug CDMO Market Size, by Manufacturing Scale, 2025 vs 2032 (%)
  • FIGURE 11. Global Small Molecule Chemical Drug CDMO Market Size, by Manufacturing Scale, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 12. Global Small Molecule Chemical Drug CDMO Market Size, by Molecule Type, 2025 vs 2032 (%)
  • FIGURE 13. Global Small Molecule Chemical Drug CDMO Market Size, by Molecule Type, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 14. Global Small Molecule Chemical Drug CDMO Market Size, by Therapeutic Area, 2025 vs 2032 (%)
  • FIGURE 15. Global Small Molecule Chemical Drug CDMO Market Size, by Therapeutic Area, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 16. Global Small Molecule Chemical Drug CDMO Market Size, by End User, 2025 vs 2032 (%)
  • FIGURE 17. Global Small Molecule Chemical Drug CDMO Market Size, by End User, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 18. Global Small Molecule Chemical Drug CDMO Market Size, by Region, 2025 vs 2032 (%)
  • FIGURE 19. Global Small Molecule Chemical Drug CDMO Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 20. Global Small Molecule Chemical Drug CDMO Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 21. Global Small Molecule Chemical Drug CDMO Market Size, by Country, 2025 vs 2032 (%)
  • FIGURE 22. Global Small Molecule Chemical Drug CDMO Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 23. Global Small Molecule Chemical Drug CDMO Market Share, by Key Player, 2025

LIST OF TABLES

  • TABLE 1. Global Small Molecule Chemical Drug CDMO Market Segmentation & Coverage
  • TABLE 2. Global Small Molecule Chemical Drug CDMO Market Size, 2017-2032 (USD Million)
  • TABLE 3. Global Small Molecule Chemical Drug CDMO Market Size, by Service Type, 2017-2032 (USD Million)
  • TABLE 4. Global Analytical Testing Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 5. Global Analytical Testing Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 6. Global Analytical Testing Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 7. Global Bioanalytical Testing Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 8. Global Bioanalytical Testing Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 9. Global Bioanalytical Testing Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 10. Global Impurity Testing Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 11. Global Impurity Testing Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 12. Global Impurity Testing Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 13. Global Method Development Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 14. Global Method Development Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 15. Global Method Development Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 16. Global Stability Testing Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 17. Global Stability Testing Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 18. Global Stability Testing Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 19. Global Clinical Development Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 20. Global Clinical Development Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 21. Global Clinical Development Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 22. Global Phase I Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 23. Global Phase I Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 24. Global Phase I Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 25. Global Phase II Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 26. Global Phase II Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 27. Global Phase II Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 28. Global Phase III Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 29. Global Phase III Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 30. Global Phase III Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 31. Global Phase IV Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 32. Global Phase IV Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 33. Global Phase IV Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 34. Global Commercial Manufacturing Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 35. Global Commercial Manufacturing Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 36. Global Commercial Manufacturing Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 37. Global Drug Product Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 38. Global Drug Product Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 39. Global Drug Product Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 40. Global Drug Substance Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 41. Global Drug Substance Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 42. Global Drug Substance Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 43. Global Formulation Development Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 44. Global Formulation Development Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 45. Global Formulation Development Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 46. Global Injectable Formulation Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 47. Global Injectable Formulation Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 48. Global Injectable Formulation Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 49. Global Oral Formulation Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 50. Global Oral Formulation Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 51. Global Oral Formulation Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 52. Global Topical Formulation Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 53. Global Topical Formulation Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 54. Global Topical Formulation Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 55. Global Preclinical Development Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 56. Global Preclinical Development Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 57. Global Preclinical Development Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 58. Global ADME Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 59. Global ADME Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 60. Global ADME Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 61. Global Pharmacokinetics Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 62. Global Pharmacokinetics Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 63. Global Pharmacokinetics Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 64. Global Safety Assessment Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 65. Global Safety Assessment Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 66. Global Safety Assessment Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 67. Global Toxicology Studies Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 68. Global Toxicology Studies Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 69. Global Toxicology Studies Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 70. Global Process Development Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 71. Global Process Development Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 72. Global Process Development Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 73. Global Process Optimization Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 74. Global Process Optimization Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 75. Global Process Optimization Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 76. Global Scale Up Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 77. Global Scale Up Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 78. Global Scale Up Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 79. Global Small Molecule Chemical Drug CDMO Market Size, by Contract Model, 2017-2032 (USD Million)
  • TABLE 80. Global Dedicated Capacity Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 81. Global Dedicated Capacity Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 82. Global Dedicated Capacity Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 83. Global Fee For Service Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 84. Global Fee For Service Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 85. Global Fee For Service Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 86. Global Risk Sharing Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 87. Global Risk Sharing Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 88. Global Risk Sharing Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 89. Global Toll Manufacturing Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 90. Global Toll Manufacturing Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 91. Global Toll Manufacturing Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 92. Global Small Molecule Chemical Drug CDMO Market Size, by Manufacturing Scale, 2017-2032 (USD Million)
  • TABLE 93. Global Clinical Scale Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 94. Global Clinical Scale Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 95. Global Clinical Scale Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 96. Global Commercial Scale Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 97. Global Commercial Scale Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 98. Global Commercial Scale Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 99. Global Pilot Scale Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 100. Global Pilot Scale Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 101. Global Pilot Scale Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 102. Global Small Molecule Chemical Drug CDMO Market Size, by Molecule Type, 2017-2032 (USD Million)
  • TABLE 103. Global Drug Product Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 104. Global Drug Product Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 105. Global Drug Product Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 106. Global Drug Substance Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 107. Global Drug Substance Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 108. Global Drug Substance Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 109. Global Small Molecule Chemical Drug CDMO Market Size, by Therapeutic Area, 2017-2032 (USD Million)
  • TABLE 110. Global Cardiovascular Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 111. Global Cardiovascular Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 112. Global Cardiovascular Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 113. Global Infectious Diseases Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 114. Global Infectious Diseases Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 115. Global Infectious Diseases Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 116. Global Neurology Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 117. Global Neurology Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 118. Global Neurology Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 119. Global Oncology Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 120. Global Oncology Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 121. Global Oncology Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 122. Global Small Molecule Chemical Drug CDMO Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 123. Global Generics Companies Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 124. Global Generics Companies Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 125. Global Generics Companies Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 126. Global Large Pharma Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 127. Global Large Pharma Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 128. Global Large Pharma Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 129. Global Small Biotech Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 130. Global Small Biotech Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 131. Global Small Biotech Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 132. Global Small Molecule Chemical Drug CDMO Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 133. Asia-Pacific Small Molecule Chemical Drug CDMO Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 134. Asia-Pacific Small Molecule Chemical Drug CDMO Market Size, by Service Type, 2017-2032 (USD Million)
  • TABLE 135. Asia-Pacific Small Molecule Chemical Drug CDMO Market Size, by Analytical Testing, 2017-2032 (USD Million)
  • TABLE 136. Asia-Pacific Small Molecule Chemical Drug CDMO Market Size, by Clinical Development, 2017-2032 (USD Million)
  • TABLE 137. Asia-Pacific Small Molecule Chemical Drug CDMO Market Size, by Commercial Manufacturing, 2017-2032 (USD Million)
  • TABLE 138. Asia-Pacific Small Molecule Chemical Drug CDMO Market Size, by Formulation Development, 2017-2032 (USD Million)
  • TABLE 139. Asia-Pacific Small Molecule Chemical Drug CDMO Market Size, by Preclinical Development, 2017-2032 (USD Million)
  • TABLE 140. Asia-Pacific Small Molecule Chemical Drug CDMO Market Size, by Process Development, 2017-2032 (USD Million)
  • TABLE 141. Asia-Pacific Small Molecule Chemical Drug CDMO Market Size, by Contract Model, 2017-2032 (USD Million)
  • TABLE 142. Asia-Pacific Small Molecule Chemical Drug CDMO Market Size, by Manufacturing Scale, 2017-2032 (USD Million)
  • TABLE 143. Asia-Pacific Small Molecule Chemical Drug CDMO Market Size, by Molecule Type, 2017-2032 (USD Million)
  • TABLE 144. Asia-Pacific Small Molecule Chemical Drug CDMO Market Size, by Therapeutic Area, 2017-2032 (USD Million)
  • TABLE 145. Asia-Pacific Small Molecule Chemical Drug CDMO Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 146. North America Small Molecule Chemical Drug CDMO Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 147. North America Small Molecule Chemical Drug CDMO Market Size, by Service Type, 2017-2032 (USD Million)
  • TABLE 148. North America Small Molecule Chemical Drug CDMO Market Size, by Analytical Testing, 2017-2032 (USD Million)
  • TABLE 149. North America Small Molecule Chemical Drug CDMO Market Size, by Clinical Development, 2017-2032 (USD Million)
  • TABLE 150. North America Small Molecule Chemical Drug CDMO Market Size, by Commercial Manufacturing, 2017-2032 (USD Million)
  • TABLE 151. North America Small Molecule Chemical Drug CDMO Market Size, by Formulation Development, 2017-2032 (USD Million)
  • TABLE 152. North America Small Molecule Chemical Drug CDMO Market Size, by Preclinical Development, 2017-2032 (USD Million)
  • TABLE 153. North America Small Molecule Chemical Drug CDMO Market Size, by Process Development, 2017-2032 (USD Million)
  • TABLE 154. North America Small Molecule Chemical Drug CDMO Market Size, by Contract Model, 2017-2032 (USD Million)
  • TABLE 155. North America Small Molecule Chemical Drug CDMO Market Size, by Manufacturing Scale, 2017-2032 (USD Million)
  • TABLE 156. North America Small Molecule Chemical Drug CDMO Market Size, by Molecule Type, 2017-2032 (USD Million)
  • TABLE 157. North America Small Molecule Chemical Drug CDMO Market Size, by Therapeutic Area, 2017-2032 (USD Million)
  • TABLE 158. North America Small Molecule Chemical Drug CDMO Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 159. Latin America Small Molecule Chemical Drug CDMO Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 160. Latin America Small Molecule Chemical Drug CDMO Market Size, by Service Type, 2017-2032 (USD Million)
  • TABLE 161. Latin America Small Molecule Chemical Drug CDMO Market Size, by Analytical Testing, 2017-2032 (USD Million)
  • TABLE 162. Latin America Small Molecule Chemical Drug CDMO Market Size, by Clinical Development, 2017-2032 (USD Million)
  • TABLE 163. Latin America Small Molecule Chemical Drug CDMO Market Size, by Commercial Manufacturing, 2017-2032 (USD Million)
  • TABLE 164. Latin America Small Molecule Chemical Drug CDMO Market Size, by Formulation Development, 2017-2032 (USD Million)
  • TABLE 165. Latin America Small Molecule Chemical Drug CDMO Market Size, by Preclinical Development, 2017-2032 (USD Million)
  • TABLE 166. Latin America Small Molecule Chemical Drug CDMO Market Size, by Process Development, 2017-2032 (USD Million)
  • TABLE 167. Latin America Small Molecule Chemical Drug CDMO Market Size, by Contract Model, 2017-2032 (USD Million)
  • TABLE 168. Latin America Small Molecule Chemical Drug CDMO Market Size, by Manufacturing Scale, 2017-2032 (USD Million)
  • TABLE 169. Latin America Small Molecule Chemical Drug CDMO Market Size, by Molecule Type, 2017-2032 (USD Million)
  • TABLE 170. Latin America Small Molecule Chemical Drug CDMO Market Size, by Therapeutic Area, 2017-2032 (USD Million)
  • TABLE 171. Latin America Small Molecule Chemical Drug CDMO Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 172. Europe Small Molecule Chemical Drug CDMO Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 173. Europe Small Molecule Chemical Drug CDMO Market Size, by Service Type, 2017-2032 (USD Million)
  • TABLE 174. Europe Small Molecule Chemical Drug CDMO Market Size, by Analytical Testing, 2017-2032 (USD Million)
  • TABLE 175. Europe Small Molecule Chemical Drug CDMO Market Size, by Clinical Development, 2017-2032 (USD Million)
  • TABLE 176. Europe Small Molecule Chemical Drug CDMO Market Size, by Commercial Manufacturing, 2017-2032 (USD Million)
  • TABLE 177. Europe Small Molecule Chemical Drug CDMO Market Size, by Formulation Development, 2017-2032 (USD Million)
  • TABLE 178. Europe Small Molecule Chemical Drug CDMO Market Size, by Preclinical Development, 2017-2032 (USD Million)
  • TABLE 179. Europe Small Molecule Chemical Drug CDMO Market Size, by Process Development, 2017-2032 (USD Million)
  • TABLE 180. Europe Small Molecule Chemical Drug CDMO Market Size, by Contract Model, 2017-2032 (USD Million)
  • TABLE 181. Europe Small Molecule Chemical Drug CDMO Market Size, by Manufacturing Scale, 2017-2032 (USD Million)
  • TABLE 182. Europe Small Molecule Chemical Drug CDMO Market Size, by Molecule Type, 2017-2032 (USD Million)
  • TABLE 183. Europe Small Molecule Chemical Drug CDMO Market Size, by Therapeutic Area, 2017-2032 (USD Million)
  • TABLE 184. Europe Small Molecule Chemical Drug CDMO Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 185. Middle East Small Molecule Chemical Drug CDMO Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 186. Middle East Small Molecule Chemical Drug CDMO Market Size, by Service Type, 2017-2032 (USD Million)
  • TABLE 187. Middle East Small Molecule Chemical Drug CDMO Market Size, by Analytical Testing, 2017-2032 (USD Million)
  • TABLE 188. Middle East Small Molecule Chemical Drug CDMO Market Size, by Clinical Development, 2017-2032 (USD Million)
  • TABLE 189. Middle East Small Molecule Chemical Drug CDMO Market Size, by Commercial Manufacturing, 2017-2032 (USD Million)
  • TABLE 190. Middle East Small Molecule Chemical Drug CDMO Market Size, by Formulation Development, 2017-2032 (USD Million)
  • TABLE 191. Middle East Small Molecule Chemical Drug CDMO Market Size, by Preclinical Development, 2017-2032 (USD Million)
  • TABLE 192. Middle East Small Molecule Chemical Drug CDMO Market Size, by Process Development, 2017-2032 (USD Million)
  • TABLE 193. Middle East Small Molecule Chemical Drug CDMO Market Size, by Contract Model, 2017-2032 (USD Million)
  • TABLE 194. Middle East Small Molecule Chemical Drug CDMO Market Size, by Manufacturing Scale, 2017-2032 (USD Million)
  • TABLE 195. Middle East Small Molecule Chemical Drug CDMO Market Size, by Molecule Type, 2017-2032 (USD Million)
  • TABLE 196. Middle East Small Molecule Chemical Drug CDMO Market Size, by Therapeutic Area, 2017-2032 (USD Million)
  • TABLE 197. Middle East Small Molecule Chemical Drug CDMO Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 198. Africa Small Molecule Chemical Drug CDMO Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 199. Africa Small Molecule Chemical Drug CDMO Market Size, by Service Type, 2017-2032 (USD Million)
  • TABLE 200. Africa Small Molecule Chemical Drug CDMO Market Size, by Analytical Testing, 2017-2032 (USD Million)
  • TABLE 201. Africa Small Molecule Chemical Drug CDMO Market Size, by Clinical Development, 2017-2032 (USD Million)
  • TABLE 202. Africa Small Molecule Chemical Drug CDMO Market Size, by Commercial Manufacturing, 2017-2032 (USD Million)
  • TABLE 203. Africa Small Molecule Chemical Drug CDMO Market Size, by Formulation Development, 2017-2032 (USD Million)
  • TABLE 204. Africa Small Molecule Chemical Drug CDMO Market Size, by Preclinical Development, 2017-2032 (USD Million)
  • TABLE 205. Africa Small Molecule Chemical Drug CDMO Market Size, by Process Development, 2017-2032 (USD Million)
  • TABLE 206. Africa Small Molecule Chemical Drug CDMO Market Size, by Contract Model, 2017-2032 (USD Million)
  • TABLE 207. Africa Small Molecule Chemical Drug CDMO Market Size, by Manufacturing Scale, 2017-2032 (USD Million)
  • TABLE 208. Africa Small Molecule Chemical Drug CDMO Market Size, by Molecule Type, 2017-2032 (USD Million)
  • TABLE 209. Africa Small Molecule Chemical Drug CDMO Market Size, by Therapeutic Area, 2017-2032 (USD Million)
  • TABLE 210. Africa Small Molecule Chemical Drug CDMO Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 211. Global Small Molecule Chemical Drug CDMO Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 212. ASEAN Small Molecule Chemical Drug CDMO Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 213. ASEAN Small Molecule Chemical Drug CDMO Market Size, by Service Type, 2017-2032 (USD Million)
  • TABLE 214. ASEAN Small Molecule Chemical Drug CDMO Market Size, by Analytical Testing, 2017-2032 (USD Million)
  • TABLE 215. ASEAN Small Molecule Chemical Drug CDMO Market Size, by Clinical Development, 2017-2032 (USD Million)
  • TABLE 216. ASEAN Small Molecule Chemical Drug CDMO Market Size, by Commercial Manufacturing, 2017-2032 (USD Million)
  • TABLE 217. ASEAN Small Molecule Chemical Drug CDMO Market Size, by Formulation Development, 2017-2032 (USD Million)
  • TABLE 218. ASEAN Small Molecule Chemical Drug CDMO Market Size, by Preclinical Development, 2017-2032 (USD Million)
  • TABLE 219. ASEAN Small Molecule Chemical Drug CDMO Market Size, by Process Development, 2017-2032 (USD Million)
  • TABLE 220. ASEAN Small Molecule Chemical Drug CDMO Market Size, by Contract Model, 2017-2032 (USD Million)
  • TABLE 221. ASEAN Small Molecule Chemical Drug CDMO Market Size, by Manufacturing Scale, 2017-2032 (USD Million)
  • TABLE 222. ASEAN Small Molecule Chemical Drug CDMO Market Size, by Molecule Type, 2017-2032 (USD Million)
  • TABLE 223. ASEAN Small Molecule Chemical Drug CDMO Market Size, by Therapeutic Area, 2017-2032 (USD Million)
  • TABLE 224. ASEAN Small Molecule Chemical Drug CDMO Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 225. GCC Small Molecule Chemical Drug CDMO Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 226. GCC Small Molecule Chemical Drug CDMO Market Size, by Service Type, 2017-2032 (USD Million)
  • TABLE 227. GCC Small Molecule Chemical Drug CDMO Market Size, by Analytical Testing, 2017-2032 (USD Million)
  • TABLE 228. GCC Small Molecule Chemical Drug CDMO Market Size, by Clinical Development, 2017-2032 (USD Million)
  • TABLE 229. GCC Small Molecule Chemical Drug CDMO Market Size, by Commercial Manufacturing, 2017-2032 (USD Million)
  • TABLE 230. GCC Small Molecule Chemical Drug CDMO Market Size, by Formulation Development, 2017-2032 (USD Million)
  • TABLE 231. GCC Small Molecule Chemical Drug CDMO Market Size, by Preclinical Development, 2017-2032 (USD Million)
  • TABLE 232. GCC Small Molecule Chemical Drug CDMO Market Size, by Process Development, 2017-2032 (USD Million)
  • TABLE 233. GCC Small Molecule Chemical Drug CDMO Market Size, by Contract Model, 2017-2032 (USD Million)
  • TABLE 234. GCC Small Molecule Chemical Drug CDMO Market Size, by Manufacturing Scale, 2017-2032 (USD Million)
  • TABLE 235. GCC Small Molecule Chemical Drug CDMO Market Size, by Molecule Type, 2017-2032 (USD Million)
  • TABLE 236. GCC Small Molecule Chemical Drug CDMO Market Size, by Therapeutic Area, 2017-2032 (USD Million)
  • TABLE 237. GCC Small Molecule Chemical Drug CDMO Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 238. European Union Small Molecule Chemical Drug CDMO Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 239. European Union Small Molecule Chemical Drug CDMO Market Size, by Service Type, 2017-2032 (USD Million)
  • TABLE 240. European Union Small Molecule Chemical Drug CDMO Market Size, by Analytical Testing, 2017-2032 (USD Million)
  • TABLE 241. European Union Small Molecule Chemical Drug CDMO Market Size, by Clinical Development, 2017-2032 (USD Million)
  • TABLE 242. European Union Small Molecule Chemical Drug CDMO Market Size, by Commercial Manufacturing, 2017-2032 (USD Million)
  • TABLE 243. European Union Small Molecule Chemical Drug CDMO Market Size, by Formulation Development, 2017-2032 (USD Million)
  • TABLE 244. European Union Small Molecule Chemical Drug CDMO Market Size, by Preclinical Development, 2017-2032 (USD Million)
  • TABLE 245. European Union Small Molecule Chemical Drug CDMO Market Size, by Process Development, 2017-2032 (USD Million)
  • TABLE 246. European Union Small Molecule Chemical Drug CDMO Market Size, by Contract Model, 2017-2032 (USD Million)
  • TABLE 247. European Union Small Molecule Chemical Drug CDMO Market Size, by Manufacturing Scale, 2017-2032 (USD Million)
  • TABLE 248. European Union Small Molecule Chemical Drug CDMO Market Size, by Molecule Type, 2017-2032 (USD Million)
  • TABLE 249. European Union Small Molecule Chemical Drug CDMO Market Size, by Therapeutic Area, 2017-2032 (USD Million)
  • TABLE 250. European Union Small Molecule Chemical Drug CDMO Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 251. BRICS Small Molecule Chemical Drug CDMO Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 252. BRICS Small Molecule Chemical Drug CDMO Market Size, by Service Type, 2017-2032 (USD Million)
  • TABLE 253. BRICS Small Molecule Chemical Drug CDMO Market Size, by Analytical Testing, 2017-2032 (USD Million)
  • TABLE 254. BRICS Small Molecule Chemical Drug CDMO Market Size, by Clinical Development, 2017-2032 (USD Million)
  • TABLE 255. BRICS Small Molecule Chemical Drug CDMO Market Size, by Commercial Manufacturing, 2017-2032 (USD Million)
  • TABLE 256. BRICS Small Molecule Chemical Drug CDMO Market Size, by Formulation Development, 2017-2032 (USD Million)
  • TABLE 257. BRICS Small Molecule Chemical Drug CDMO Market Size, by Preclinical Development, 2017-2032 (USD Million)
  • TABLE 258. BRICS Small Molecule Chemical Drug CDMO Market Size, by Process Development, 2017-2032 (USD Million)
  • TABLE 259. BRICS Small Molecule Chemical Drug CDMO Market Size, by Contract Model, 2017-2032 (USD Million)
  • TABLE 260. BRICS Small Molecule Chemical Drug CDMO Market Size, by Manufacturing Scale, 2017-2032 (USD Million)
  • TABLE 261. BRICS Small Molecule Chemical Drug CDMO Market Size, by Molecule Type, 2017-2032 (USD Million)
  • TABLE 262. BRICS Small Molecule Chemical Drug CDMO Market Size, by Therapeutic Area, 2017-2032 (USD Million)
  • TABLE 263. BRICS Small Molecule Chemical Drug CDMO Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 264. G7 Small Molecule Chemical Drug CDMO Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 265. G7 Small Molecule Chemical Drug CDMO Market Size, by Service Type, 2017-2032 (USD Million)
  • TABLE 266. G7 Small Molecule Chemical Drug CDMO Market Size, by Analytical Testing, 2017-2032 (USD Million)
  • TABLE 267. G7 Small Molecule Chemical Drug CDMO Market Size, by Clinical Development, 2017-2032 (USD Million)
  • TABLE 268. G7 Small Molecule Chemical Drug CDMO Market Size, by Commercial Manufacturing, 2017-2032 (USD Million)
  • TABLE 269. G7 Small Molecule Chemical Drug CDMO Market Size, by Formulation Development, 2017-2032 (USD Million)
  • TABLE 270. G7 Small Molecule Chemical Drug CDMO Market Size, by Preclinical Development, 2017-2032 (USD Million)
  • TABLE 271. G7 Small Molecule Chemical Drug CDMO Market Size, by Process Development, 2017-2032 (USD Million)
  • TABLE 272. G7 Small Molecule Chemical Drug CDMO Market Size, by Contract Model, 2017-2032 (USD Million)
  • TABLE 273. G7 Small Molecule Chemical Drug CDMO Market Size, by Manufacturing Scale, 2017-2032 (USD Million)
  • TABLE 274. G7 Small Molecule Chemical Drug CDMO Market Size, by Molecule Type, 2017-2032 (USD Million)
  • TABLE 275. G7 Small Molecule Chemical Drug CDMO Market Size, by Therapeutic Area, 2017-2032 (USD Million)
  • TABLE 276. G7 Small Molecule Chemical Drug CDMO Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 277. NATO Small Molecule Chemical Drug CDMO Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 278. NATO Small Molecule Chemical Drug CDMO Market Size, by Service Type, 2017-2032 (USD Million)
  • TABLE 279. NATO Small Molecule Chemical Drug CDMO Market Size, by Analytical Testing, 2017-2032 (USD Million)
  • TABLE 280. NATO Small Molecule Chemical Drug CDMO Market Size, by Clinical Development, 2017-2032 (USD Million)
  • TABLE 281. NATO Small Molecule Chemical Drug CDMO Market Size, by Commercial Manufacturing, 2017-2032 (USD Million)
  • TABLE 282. NATO Small Molecule Chemical Drug CDMO Market Size, by Formulation Development, 2017-2032 (USD Million)
  • TABLE 283. NATO Small Molecule Chemical Drug CDMO Market Size, by Preclinical Development, 2017-2032 (USD Million)
  • TABLE 284. NATO Small Molecule Chemical Drug CDMO Market Size, by Process Development, 2017-2032 (USD Million)
  • TABLE 285. NATO Small Molecule Chemical Drug CDMO Market Size, by Contract Model, 2017-2032 (USD Million)
  • TABLE 286. NATO Small Molecule Chemical Drug CDMO Market Size, by Manufacturing Scale, 2017-2032 (USD Million)
  • TABLE 287. NATO Small Molecule Chemical Drug CDMO Market Size, by Molecule Type, 2017-2032 (USD Million)
  • TABLE 288. NATO Small Molecule Chemical Drug CDMO Market Size, by Therapeutic Area, 2017-2032 (USD Million)
  • TABLE 289. NATO Small Molecule Chemical Drug CDMO Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 290. Global Small Molecule Chemical Drug CDMO Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 291. United States Small Molecule Chemical Drug CDMO Market Size, 2017-2032 (USD Million)
  • TABLE 292. United States Small Molecule Chemical Drug CDMO Market Size, by Service Type, 2017-2032 (USD Million)
  • TABLE 293. United States Small Molecule Chemical Drug CDMO Market Size, by Analytical Testing, 2017-2032 (USD Million)
  • TABLE 294. United States Small Molecule Chemical Drug CDMO Market Size, by Clinical Development, 2017-2032 (USD Million)
  • TABLE 295. United States Small Molecule Chemical Drug CDMO Market Size, by Commercial Manufacturing, 2017-2032 (USD Million)
  • TABLE 296. United States Small Molecule Chemical Drug CDMO Market Size, by Formulation Development, 2017-2032 (USD Million)
  • TABLE 297. United States Small Molecule Chemical Drug CDMO Market Size, by Preclinical Development, 2017-2032 (USD Million)
  • TABLE 298. United States Small Molecule Chemical Drug CDMO Market Size, by Process Development, 2017-2032 (USD Million)
  • TABLE 299. United States Small Molecule Chemical Drug CDMO Market Size, by Contract Model, 2017-2032 (USD Million)
  • TABLE 300. United States Small Molecule Chemical Drug CDMO Market Size, by Manufacturing Scale, 2017-2032 (USD Million)
  • TABLE 301. United States Small Molecule Chemical Drug CDMO Market Size, by Molecule Type, 2017-2032 (USD Million)
  • TABLE 302. United States Small Molecule Chemical Drug CDMO Market Size, by Therapeutic Area, 2017-2032 (USD Million)
  • TABLE 303. United States Small Molecule Chemical Drug CDMO Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 304. Canada Small Molecule Chemical Drug CDMO Market Size, 2017-2032 (USD Million)
  • TABLE 305. Canada Small Molecule Chemical Drug CDMO Market Size, by Service Type, 2017-2032 (USD Million)
  • TABLE 306. Canada Small Molecule Chemical Drug CDMO Market Size, by Analytical Testing, 2017-2032 (USD Million)
  • TABLE 307. Canada Small Molecule Chemical Drug CDMO Market Size, by Clinical Development, 2017-2032 (USD Million)
  • TABLE 308. Canada Small Molecule Chemical Drug CDMO Market Size, by Commercial Manufacturing, 2017-2032 (USD Million)
  • TABLE 309. Canada Small Molecule Chemical Drug CDMO Market Size, by Formulation Development, 2017-2032 (USD Million)
  • TABLE 310. Canada Small Molecule Chemical Drug CDMO Market Size, by Preclinical Development, 2017-2032 (USD Million)
  • TABLE 311. Canada Small Molecule Chemical Drug CDMO Market Size, by Process Development, 2017-2032 (USD Million)
  • TABLE 312. Canada Small Molecule Chemical Drug CDMO Market Size, by Contract Model, 2017-2032 (USD Million)
  • TABLE 313. Canada Small Molecule Chemical Drug CDMO Market Size, by Manufacturing Scale, 2017-2032 (USD Million)
  • TABLE 314. Canada Small Molecule Chemical Drug CDMO Market Size, by Molecule Type, 2017-2032 (USD Million)
  • TABLE 315. Canada Small Molecule Chemical Drug CDMO Market Size, by Therapeutic Area, 2017-2032 (USD Million)
  • TABLE 316. Canada Small Molecule Chemical Drug CDMO Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 317. Mexico Small Molecule Chemical Drug CDMO Market Size, 2017-2032 (USD Million)
  • TABLE 318. Mexico Small Molecule Chemical Drug CDMO Market Size, by Service Type, 2017-2032 (USD Million)
  • TABLE 319. Mexico Small Molecule Chemical Drug CDMO Market Size, by Analytical Testing, 2017-2032 (USD Million)
  • TABLE 320. Mexico Small Molecule Chemical Drug CDMO Market Size, by Clinical Development, 2017-2032 (USD Million)
  • TABLE 321. Mexico Small Molecule Chemical Drug CDMO Market Size, by Commercial Manufacturing, 2017-2032 (USD Million)
  • TABLE 322. Mexico Small Molecule Chemical Drug CDMO Market Size, by Formulation Development, 2017-2032 (USD Million)
  • TABLE 323. Mexico Small Molecule Chemical Drug CDMO Market Size, by Preclinical Development, 2017-2032 (USD Million)
  • TABLE 324. Mexico Small Molecule Chemical Drug CDMO Market Size, by Process Development, 2017-2032 (USD Million)
  • TABLE 325. Mexico Small Molecule Chemical Drug CDMO Market Size, by Contract Model, 2017-2032 (USD Million)
  • TABLE 326. Mexico Small Molecule Chemical Drug CDMO Market Size, by Manufacturing Scale, 2017-2032 (USD Million)
  • TABLE 327. Mexico Small Molecule Chemical Drug CDMO Market Size, by Molecule Typ